Clinical Trial

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a randomized controlled study to assess the effect of atorvastatin and omega 3 combination therapy compared with atorvastatin and ezetimibe combination therapy in Korean T2DM patients with asymptomatic atherosclerosis.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-05-03; most recent amendment 2026-05-02.
Status change: Not Yet Recruiting → Recruiting 2022-10-01
Trial Details
NCT Number NCT05365438
Lead Sponsor Seoul National University Bundang Hospital
Collaborators: Korea United Pharm. Inc.
Conditions Dyslipidemias, Atherosclerosis, Diabetes Mellitus, Type 2
Enrollment 105 participants
Start Date 2022-10-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-05